Abstract
Tuberculosis (TB) is a leading cause of mortality due to an infectious agent. TB primarily targets the lungs but in about 16% cases can affect other organs as well, giving rise to extrapulmonary TB (EPTB). However, an optimal regimen for EPTB treatment is not defined. While the recommended treatment for most forms of EPTB is the same as pulmonary TB, pharmacokinetics of EPTB therapy are not as well-studied. To address this gap, we formulate a whole-body physiologically-based pharmacokinetic (PBPK) model for EPTB that for the first time includes the ability to simulate drug concentrations in the pleura and lymph node. Using this model, we estimate the time-dependent concentrations, at potential EPTB infection sites, of the 4 first-line anti-TB drugs: Rifampicin, Ethambutol, Isoniazid and Pyrazinamide. We utilise reported plasma concentration kinetics data to estimate model parameters for each drug, and validate our model using reported concentration data not used for model formulation or parameter estimation. Model predictions match the validation data and reported PK parameters (Cmax, tmax) for the drugs. The model also predicts Ethambutol, Isoniazid and Pyrazinamide concentrations in the pleura that match reported experimental values from an independent study. For each drug, the model is used to simulate the time-dependent drug concentrations at various EPTB sites. Predicted drug concentrations are compared to their critical concentration. Simulations suggest that while Rifampicin and Isoniazid concentrations are greater than critical concentration values at most EPTB sites, the concentrations of Ethambutol and Pyrazinamide are lower than their critical concentrations at most EPTB sites.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Council of Scientific and Industrial Research in the form of a fellowship to Aparna Ramachandran; and Department of Biotechnology in the form of a research grant to Chetan Gadgil (BT/PR40128/BTIS/37/43/2022)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest: All authors declared no competing interests for this work
Funding Information: Funding from Council of Scientific and Industrial Research in the form of a fellowship to Aparna Ramachandran; and from Department of Biotechnology in the form of a research grant to Chetan Gadgil (BT/PR40128/BTIS/37/43/2022)
Data Availability
All Matlab codes used to produce the data in the present study are available upon reasonable request to the authors
